| node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
| CYB5A | CYB5R3 | ENSP00000341625 | ENSP00000354468 | Cytochrome b5; Cytochrome b5 is a membrane bound hemoprotein which function as an electron carrier for several membrane bound oxygenases | NADH-cytochrome b5 reductase 3; Desaturation and elongation of fatty acids, cholesterol biosynthesis, drug metabolism, and, in erythrocyte, methemoglobin reduction | 0.995 |
| CYB5A | MARC1 | ENSP00000341625 | ENSP00000355877 | Cytochrome b5; Cytochrome b5 is a membrane bound hemoprotein which function as an electron carrier for several membrane bound oxygenases | Mitochondrial amidoxime-reducing component 1; As a component of an N-hydroxylated prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively | 0.547 |
| CYB5A | MARC2 | ENSP00000341625 | ENSP00000355880 | Cytochrome b5; Cytochrome b5 is a membrane bound hemoprotein which function as an electron carrier for several membrane bound oxygenases | Mitochondrial amidoxime reducing component 2; As a component of the benzamidoxime prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively | 0.594 |
| CYB5B | CYB5R3 | ENSP00000308430 | ENSP00000354468 | Cytochrome b5 type B; Cytochrome b5 is a membrane bound hemoprotein which function as an electron carrier for several membrane bound oxygenases | NADH-cytochrome b5 reductase 3; Desaturation and elongation of fatty acids, cholesterol biosynthesis, drug metabolism, and, in erythrocyte, methemoglobin reduction | 0.971 |
| CYB5B | MARC1 | ENSP00000308430 | ENSP00000355877 | Cytochrome b5 type B; Cytochrome b5 is a membrane bound hemoprotein which function as an electron carrier for several membrane bound oxygenases | Mitochondrial amidoxime-reducing component 1; As a component of an N-hydroxylated prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively | 0.959 |
| CYB5B | MARC2 | ENSP00000308430 | ENSP00000355880 | Cytochrome b5 type B; Cytochrome b5 is a membrane bound hemoprotein which function as an electron carrier for several membrane bound oxygenases | Mitochondrial amidoxime reducing component 2; As a component of the benzamidoxime prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively | 0.967 |
| CYB5R3 | CYB5A | ENSP00000354468 | ENSP00000341625 | NADH-cytochrome b5 reductase 3; Desaturation and elongation of fatty acids, cholesterol biosynthesis, drug metabolism, and, in erythrocyte, methemoglobin reduction | Cytochrome b5; Cytochrome b5 is a membrane bound hemoprotein which function as an electron carrier for several membrane bound oxygenases | 0.995 |
| CYB5R3 | CYB5B | ENSP00000354468 | ENSP00000308430 | NADH-cytochrome b5 reductase 3; Desaturation and elongation of fatty acids, cholesterol biosynthesis, drug metabolism, and, in erythrocyte, methemoglobin reduction | Cytochrome b5 type B; Cytochrome b5 is a membrane bound hemoprotein which function as an electron carrier for several membrane bound oxygenases | 0.971 |
| CYB5R3 | MARC1 | ENSP00000354468 | ENSP00000355877 | NADH-cytochrome b5 reductase 3; Desaturation and elongation of fatty acids, cholesterol biosynthesis, drug metabolism, and, in erythrocyte, methemoglobin reduction | Mitochondrial amidoxime-reducing component 1; As a component of an N-hydroxylated prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively | 0.946 |
| CYB5R3 | MARC2 | ENSP00000354468 | ENSP00000355880 | NADH-cytochrome b5 reductase 3; Desaturation and elongation of fatty acids, cholesterol biosynthesis, drug metabolism, and, in erythrocyte, methemoglobin reduction | Mitochondrial amidoxime reducing component 2; As a component of the benzamidoxime prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively | 0.955 |
| CYB5R3 | SUOX | ENSP00000354468 | ENSP00000377668 | NADH-cytochrome b5 reductase 3; Desaturation and elongation of fatty acids, cholesterol biosynthesis, drug metabolism, and, in erythrocyte, methemoglobin reduction | Sulfite oxidase, mitochondrial; Sulfite oxidase | 0.516 |
| GGCX | MARC1 | ENSP00000233838 | ENSP00000355877 | Vitamin K-dependent gamma-carboxylase; Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium-binding gamma-carboxyglutamate (Gla) residues with the concomitant conversion of the reduced hydroquinone form of vitamin K to vitamin K epoxide | Mitochondrial amidoxime-reducing component 1; As a component of an N-hydroxylated prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively | 0.585 |
| GGCX | MARC2 | ENSP00000233838 | ENSP00000355880 | Vitamin K-dependent gamma-carboxylase; Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium-binding gamma-carboxyglutamate (Gla) residues with the concomitant conversion of the reduced hydroquinone form of vitamin K to vitamin K epoxide | Mitochondrial amidoxime reducing component 2; As a component of the benzamidoxime prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively | 0.406 |
| GLT1D1 | MARC1 | ENSP00000281703 | ENSP00000355877 | Glycosyltransferase 1 domain-containing protein 1; Glycosyl transferases group 1 domain containing; Belongs to the glycosyltransferase group 1 family. Glycosyltransferase 4 subfamily | Mitochondrial amidoxime-reducing component 1; As a component of an N-hydroxylated prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively | 0.665 |
| GLT1D1 | MARC2 | ENSP00000281703 | ENSP00000355880 | Glycosyltransferase 1 domain-containing protein 1; Glycosyl transferases group 1 domain containing; Belongs to the glycosyltransferase group 1 family. Glycosyltransferase 4 subfamily | Mitochondrial amidoxime reducing component 2; As a component of the benzamidoxime prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively | 0.406 |
| MARC1 | CYB5A | ENSP00000355877 | ENSP00000341625 | Mitochondrial amidoxime-reducing component 1; As a component of an N-hydroxylated prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively | Cytochrome b5; Cytochrome b5 is a membrane bound hemoprotein which function as an electron carrier for several membrane bound oxygenases | 0.547 |
| MARC1 | CYB5B | ENSP00000355877 | ENSP00000308430 | Mitochondrial amidoxime-reducing component 1; As a component of an N-hydroxylated prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively | Cytochrome b5 type B; Cytochrome b5 is a membrane bound hemoprotein which function as an electron carrier for several membrane bound oxygenases | 0.959 |
| MARC1 | CYB5R3 | ENSP00000355877 | ENSP00000354468 | Mitochondrial amidoxime-reducing component 1; As a component of an N-hydroxylated prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively | NADH-cytochrome b5 reductase 3; Desaturation and elongation of fatty acids, cholesterol biosynthesis, drug metabolism, and, in erythrocyte, methemoglobin reduction | 0.946 |
| MARC1 | GGCX | ENSP00000355877 | ENSP00000233838 | Mitochondrial amidoxime-reducing component 1; As a component of an N-hydroxylated prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively | Vitamin K-dependent gamma-carboxylase; Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium-binding gamma-carboxyglutamate (Gla) residues with the concomitant conversion of the reduced hydroquinone form of vitamin K to vitamin K epoxide | 0.585 |
| MARC1 | GLT1D1 | ENSP00000355877 | ENSP00000281703 | Mitochondrial amidoxime-reducing component 1; As a component of an N-hydroxylated prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxime. Also able to reduce N(omega)-hydroxy-L-arginine (NOHA) and N(omega)-hydroxy-N(delta)-methyl-L-arginine (NHAM) into L-arginine and N(delta)-methyl-L-arginine, respectively | Glycosyltransferase 1 domain-containing protein 1; Glycosyl transferases group 1 domain containing; Belongs to the glycosyltransferase group 1 family. Glycosyltransferase 4 subfamily | 0.665 |
